Evidence map›Paper›PMID 24866496›Full record

Trial reportExperimental gerontology2014

Safety and metabolic outcomes of resveratrol supplementation in older adults: results of a twelve-week, placebo-controlled pilot study.

Stephen D Anton, Chelsea Embry, Michael Marsiske, Xiaomin Lu, Hani Doss, Christiaan Leeuwenburgh, Todd M Manini

Registry-linked trialOpen access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Experimental gerontology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04317287 (A Double-blind, Randomized, Placebo-controlled, Parallel Design Study to Evaluate the Effects of the Cardio Formulation on Oxidized LDL in Individuals Who Are Overweight to Mildly Obese and Otherwise Healthy), which is not on this map. Cited by 45 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 8 pooled it
3.9field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04317287 naterminatednot on this mapstarted 2019, after this paper: background citation

A Double-blind, Randomized, Placebo-controlled, Parallel Design Study to Evaluate the Effects of the Cardio Formulation on Oxidized LDL in Individuals Who Are Overweight to Mildly Obese and Otherwise Healthy

TypeinterventionalSponsorSupplement Formulators, Inc.Ran2019 to 2021Enrolled9ConditionsOxidized Low Density LipoproteinArmsCardio formulation, Placebo
3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 8 syntheses or guidelines pooled it, 88 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Effects of 90 Days of Resveratrol Supplementation on Cognitive Function in Elders: A Pilot Study.Journal of alternative and complementary medicine (New York, N.Y.) · 2018
    Trial
  12. Trial
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Stephen D AntonDepartment of Aging and Geriatric Research, University of Florida, Gainesville, FL, USA; Department of Clinical and Health Psychology, University of Florida, Gainesville, FL, USA. Electronic address: santon@ufl.edu.
Chelsea EmbryProgressive Medical Research, Port Orange, FL, USA.
Michael MarsiskeDepartment of Clinical and Health Psychology, University of Florida, Gainesville, FL, USA.
Xiaomin LuDepartment of Biostatistics, University of Florida, Gainesville, FL, USA.
Hani DossDepartment of Statistics, University of Florida, Gainesville, FL, USA.
Christiaan LeeuwenburghDepartment of Aging and Geriatric Research, University of Florida, Gainesville, FL, USA.
Todd M ManiniDepartment of Aging and Geriatric Research, University of Florida, Gainesville, FL, USA. Electronic address: tmanini@ufl.edu.
University of Florida · USUniversity of Florida Health · US

Funding

University of Florida Older Americans Independence Center (OAIC)P30AG028740 · NIA · UNIVERSITY OF FLORIDA · PI Karyn A Esser, Todd Manini · 2007 to 2026
$22.8M
UF Clinical and Translational Science AwardUL1TR000064 · NCATS · UNIVERSITY OF FLORIDA · PI NELSON, DAVID R · 2012 to 2014
$12.2M
Investigations of botanicals on food intake, satiety, weight loss, and oxidativeK23AT004251 · NCCIH · UNIVERSITY OF FLORIDA · PI ANTON, STEPHEN D · 2009 to 2013
$575k
NCATS NIH HHS UL1 TR000064NCATS NIH HHS UL1TR000064NCCIH NIH HHS K23 AT004251NIA NIH HHS P30 AG028740NIA NIH HHS P30AG028740
6 · The paper itself

Abstract

Resveratrol has been found to have potent antioxidant, anti-inflammatory, and anticarcinogenic effects. The safety and efficacy of resveratrol supplementation in older adults are currently unknown. We conducted a double-blind, randomized, placebo-controlled trial to examine the safety and metabolic outcomes in 32 overweight, older adults (mean age, 73±7years). Participants were randomized into one of three treatment groups: (1) placebo, (2) moderate dose resveratrol (300mg/day), and (3) high dose resveratrol (1000mg/day). Both resveratrol and placebo were orally ingested in capsule form twice daily for 90days. Blood chemistry values remained within the normal range, and there were no significant differences in the number of participants reporting adverse events across conditions. Compared to placebo, glucose levels were significantly lower at post-treatment among participants randomized to both resveratrol conditions, with and without adjustment for the corresponding baseline values (ps<0.05). Glucose values of participants in the treatment groups, however, were not significantly different from baseline levels. These findings suggest that short-term resveratrol supplementation at doses of 300mg/day and 1000mg/day does not adversely affect blood chemistries and is well tolerated in overweight, older individuals. These findings support the study of resveratrol for improving cardio-metabolic health in older adults in larger clinical trials.

Indexed as

AgedAnthropometryAnti-Inflammatory Agents, Non-SteroidalBlood GlucoseBlood PressureDietary SupplementsFemaleHumansMaleOverweightPilot ProjectsResveratrolStilbenesWaist CircumferenceAnti-Inflammatory Agents, Non-SteroidalBlood GlucoseResveratrolStilbenesBlood pressureGlucoseMetabolismResveratrolSafety

Identifiers

PMID24866496
PMCPMC4149922
OpenAlexW2077214005

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.